iconiifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Sun Pharmaceutical Industries: Sustained efforts to drive growth in Specialty

17 Mar 2023 , 11:13 AM

Recommendation: Buy

Target Price: Rs 1,150

 

Analysts at IIFL Securities believe Deuruxolitinib provides a compelling opportunity to drive medium-term growth in the company’s Specialty business, given Deuruxo’s best-in-class efficacy profile, limited competition in the Alopecia Areata (AA) market from new-age drugs, and prescriber/commercial infrastructure overlap between Sun’s existing derma products and Deuruxo. With nominal market share (MS) assumption of 5% and pricing largely similar to Eli Lilly’s Olumiant, analysts at IIFL Securities believe Deuruxo could garner peak US/global sales of USD500/650 million in FY34/35 and estimate its NPV to be USD900 million (Rs30/share). Every 100 basis points increase in MS would add USD130 million to IIFL Securities’ global sales estimate for FY34. With robust execution in Specialty/India business and low dependence on US Generics (only 12-14% of overall EBITDA), Sun remains the top-pick of IIFL Securities in the large-cap Pharma space.

AA – a potential USD3.5-4 billion market in the making

AA’s prevalence in the US is 0.21%, with ~40% of the patients suffering from moderate to severe disease (>50% loss of scalp hair). While there are only 300K moderate to severe AA patients in the US, there are limited new-age treatment options with Eli Lilly’s Olumiant being the only approved product currently. Given Olumiant’s net pricing (IIFLe) of USD24K per patient per year, analysts at IIFL Securities believe AA could become a USD3.5-4 billion market in the US over the next decade, provided half of the severe AA patients start treatment with new-age oral JAK inhibitors.

Estimate Deuruxo’s NPV to be USD900 million (Rs30/share) for Sun

Sun’s Deuruxo efficacy at 38-42% is higher than that of Eli Lilly’s Olumiant (32-35%) and Pfizer’s Ritlecitinib (30%, filed with USFDA). Assuming 5% MS for Deuruxo in moderate to severe AA patients and the pricing similar to Olumiant, analysts at IIFL Securities believe Deuruxo could garner peak US/global sales of USD500/650 million in FY34/35, with potential EBITDA margins of 55-60% (90% GMs, 10% royalty expenses and 20-25% SG&A/R&D costs).

Analysts at IIFL Securities expect Concert’s annual EBITDA drag to be USD75-100 million p.a. over FY24-26

This will largely be offset by the Revlimid opportunity for Sun. Although Concert will depress Sun’s earnings for the initial 3-year period, analysts at IIFL Securities expect Deuruxo to contribute cumulative post-tax profits of USD2.2 billion to Sun during the product’s remaining 14-year patent lifetime.

 

Related Tags

  • Sun Pharma
  • Sun Pharmaceutical
  • Sun Pharmaceutical Industries
sidebar mobile

BLOGS AND PERSONAL FINANCE

Images
28 Mar 2024   |   03:36 PM
Images
28 Mar 2024   |   03:01 PM
Images
28 Mar 2024   |   01:21 PM
Images
28 Mar 2024   |   01:02 PM
Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.